These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24920911)

  • 1. Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.
    Mukherji D; El Dika I; Temraz S; Haidar M; Shamseddine A
    Ther Clin Risk Manag; 2014; 10():373-80. PubMed ID: 24920911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 for the treatment of prostate cancer.
    Hafeez S; Parker C
    Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.
    Gartrell BA; Saad F
    Ther Adv Urol; 2015 Aug; 7(4):194-202. PubMed ID: 26445599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 in metastatic castration resistant prostate cancer.
    Vuong W; Sartor O; Pal SK
    Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
    Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
    Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.
    Jiménez Romero ME; Díez Farto S; Navarro Serrato JS; Canelón Castillo E; Revelo Cadena I
    Exp Oncol; 2018 Jun; 40(2):144-148. PubMed ID: 29949528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
    Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.